Press Release
May 8, 2012
In a challenging business environment, DSM continued to make good progress in Q1 and the robust results represent a positive start to 2012.
Heerlen, NL, 08 May 2012 07:15 CEST
Commenting on the results, Feike Sijbesma, CEO/Chairman of the DSM Managing Board, said: “In a challenging business environment, DSM continued to make good progress in Q1 and the robust results represent a positive start to 2012. In Life Sciences, Nutrition continued to deliver excellent performance despite the currency headwinds, benefiting from the acquisition of Martek and continued organic growth. Materials Sciences delivered an improved performance compared to the previous quarter in Performance Materials and another good result in Polymer Intermediates.
“We continue to make important steps in the execution of our strategy. During the quarter we established the joint venture with US based POET, one of the world’s largest bio-ethanol producers, to unlock the exciting potential of advanced cellulosic biofuels. Last week we announced the execution of a Merger Agreement with Kensey Nash and planned tender offer, which will put DSM Biomedical clearly on the map as the second new growth platform for DSM in addition to our Bio-based Products & Services business.
“DSM has successfully transformed itself into a Life Sciences and Materials Sciences company. Our attractive portfolio in health, nutrition and materials together with our broad geographic spread with a significant presence in high growth economies and our very strong balance sheet has positioned us well to deliver shareholder value with stronger, more stable growth and profitability. We remain cautiously optimistic for 2012 despite the uncertain macro-economic situation.”
| in € million | Q1 2012 | Q1 2011 | +/- |
|---|---|---|---|
| Continuing operations | |||
| Net sales | 2,290 | 2,234 | 3% |
| Operating profit before depreciation & amortization (EBITDA) | 306 | 325 | -6% |
| Nutrition | 192 | 173 | |
| Pharma | 5 | 0 | |
| Performance Materials | 79 | 91 | |
| Polymer Intermediates | 69 | 99 | |
| Innovation Center | -15 | -13 | |
| Corporate activities | -24 | -25 | |
| Operating profit (EBIT) | 200 | 231 | -13% |
| Discontinued operations | |||
| Net sales | 111 | ||
| Operating profit before depreciation & amortization (EBITDA) | 23 | ||
| Operating profit (EBIT) | 23 | ||
| Total DSM | |||
| Net sales | 2,290 | 2,345 | -2% |
| Operating profit before depreciation & amortization (EBITDA) | 306 | 348 | -12% |
| Net profit before exceptional items | 145 | 172 | -16% |
| Net result from exceptional items | -6 | ||
| Net profit | 145 | 166 | -13% |
| Net profit per share in €: | |||
| before exceptional items, continuing operations | 0.87 | 0.91 | -4% |
| including exceptional items, total DSM | 0.87 | 0.98 | -11% |
You can find the press release in full, including financial statements, below.
Senior Communications Manager
+31 45 578 2420
media.contacts@dsm.com
Vice President Investor Relations
+31 45 578 2864
investor.relations@dsm.com
+31 45 578 2420
+31 45 578 2864